Listen to Ashley Jensen discuss SIWA’s antibody at AACR’s Virtual Conference!
https://youtu.be/iMSnFTNbsyo
New antibody shows strong potential against pancreatic cancer
SIWA318H specifically targets and removes senescent cells in pancreatic tumors, slowing their growth PHOENIX, AZ — Oct. 12, 2023 — Scientists at the Translational Genomics Research Institute (TGen), part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product (AGE)-targeting antibody, in the fight against pancreatic cancer. The results appear in Scientific Reports, a Nature publication. Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), has long been known for its aggressive nature and resistance to current treatment options. SIWA318H’s ability to selectively target senescent cells represents a new approach to treating the disease. Senescent cells within the tumor microenvironment have been identified as major contributors to tumor development, growth and therapy resistance. SIWA318H, an antibody specifically designed to target AGEs, offers…
SIWA Therapeutics, Inc. Presents New Data at the November 2022 American Association for Cancer Research Aging and Cancer Conference
You can view the poster by clicking here.Chicago, IL., November 21, 2022, The aging-related and cancer cell-derived oxidatively-stressed tumor microenvironment and other cell damages drive cell senescence and other oxidative cellular responses. Tumor fibrosis reduces the effectiveness of anti-cancer immune responses and senescent cells (SCs), in turn, promote immune suppression, tumor progression, and metastasis. Hence, according to a study conducted by Translational Genomics Research Institute on behalf of SIWA Therapeutics, Inc. as presented by Dr. Gabriela Rossi, Chief Research Officer of SIWA Therapeutics, Inc. (“SIWA”) at the AACR Special Conference: Aging and Cancer November 17 -20, 2022, targeting damaged cells, including SCs and cancer cells, with SIWA318H, presents an attractive approach for cancer therapy. SIWA318H is a monoclonal antibody that selectively targets an advanced glycation end product oxidative stress biomarker…
SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study
CHICAGO, March 14, 2022 -- PRNewswire -- SIWA Therapeutics, Inc. (“SIWA”), a Chicago-based biopharmaceutical company announced today that SIWA’s proprietary humanized monoclonal antibody, SIWA318H, is efficacious in an immune competent humanized mouse xenograft model for pancreatic cancer. The study was conducted by the Translational Genomics research Institute (“TGEN”), pursuant to a SIWA-sponsored research agreement. Results of the pancreatic cancer study in humanized mice treated with SIWA318H included: Both the SIWA318H high dose and low dose treatment groups showed significant anti-tumor activity in a PSN1 human pancreatic cancer mouse xenograft tumor model by significantly reducing tumor growth (P-Value < 0.0001); There was a significantly higher number of complete remission cases in the treated groups compared to the isotype-treated control group. 37.5% (6 out of 16 mice) treated with SIWA318H high dose had…
SIWA Therapeutics, Inc. Appoints Deborah Wince-Smith to Board of Directors
CHICAGO, Feb. 24, 2022 /PRNewswire/ -- SIWA THERAPEUTICS, INC, which has developed SIWA318H, a proprietary monoclonal antibody that has caused complete remission of pancreatic cancer in vivo in humanized mice, announced today that it has appointed Deborah Wince-Smith to its Board of Directors, effective February 22, 2022.Ms. Wince-Smith is the President and CEO of the Council on Competitiveness, a coalition of CEOs, university presidents, labor leaders and national laboratory directors, committed to driving U.S. competitiveness. She has more than 20 years of experience as a senior U.S. government official, as the first Senate-confirmed Assistant Secretary for Technology Policy in the U.S. Department of Commerce in the Administration of President George H.W. Bush, and as the Assistant Director for International Affairs in the White House Office of Science and Technology Policy in the Reagan Administration. She served as…
Listen to Lewis Gruber speak at the 2021 Metabestiy conference
https://www.youtube.com/watch?v=8l8yrq4kmPE&t=1s
Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!
https://www.youtube.com/embed/i9ZE3lS1R7s
In The News: Supertrends
SIWA CEO and Chief Scientific Officer, Lewis Gruber, was featured in a recent interview with Supertrends where he discussed how SIWA 318H targets cancerous, senescent, and virally infected cells. Read the full interview here: https://www.supertrends.com/senolytics-showcase-link-between-life-extension-and-therapeutics/
Press Release: SIWA Therapeutics Grows Leadership Team with Appointment of Gabriela Rossi, Ph.D.
Read more here: https://www.biospace.com/article/siwa-therapeutics-grows-leadership-team-with-appointment-of-gabriela-rossi-ph-d-/
In The News: Startup.info Interview
"While SIWA’s focus remains on developing a powerful therapeutic for aggressive cancers, the Covid-19 pandemic presented us with an opportunity to explore how 318H could also be used to treat infectious diseases." In this interview, our CEO and Chief Scientific Officer, Lewis Gruber, discusses the results of our recent preclinical tests, which confirmed 318H shows promise to become both a comprehensive cancer therapy and a broad-spectrum antiviral drug. Read the full interview here: https://startup.info/lewis-gruber-siwa-therapeutics/